EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Efficacy and tolerability of fenfluramine with concomitant potassium bromide in patients with Dravet syndrome

Milka Pringsheim, Gerhard Kluger, Adam Strzelczyk iD, Susanne Schubert-Bast iD, Thomas Mayer, Benjamin Glauche, Hiltrud Muhle, Michael Alber, Hartwig Spors, Tilmann Polster iD, Regina Trollmann iD, Gerhard Kurlemann und 2 weitere

Epilepsia Open · 2025

DOI: 10.1002/epi4.70079 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Epilepsia Open, 2025. Verfasst von Milka Pringsheim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Neuropediatrics and Neurorehabilitation, Epilepsy Center for Children and Adolescents, Schön Klinik Vogtareuth, Vogtareuth, Germany. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Bromides, Potassium Compounds, Fenfluramine. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: LOEWE - Personalized Translational Epilepsy Research, Goethe University Frankfurt, Faculty of Medicine, University of Freiburg, Medizinische Fakultät der Albert-Ludwigs-Universität Freiburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the efficacy and tolerability of fenfluramine (FFA) with concomitant potassium bromide (BR) in patients with Dravet syndrome (DS).

Methods

This multicenter retrospective study, conducted within the German compassionate use program, analyzed BR doses and serum levels before and after FFA initiation, adverse events (AEs), seizure reduction, and symptoms changes using the Clinical Global Impression of Change (CGIC) scale. Timepoints were defined as T0 (baseline), T1 (FFA initiation), T2 and T3 (first and second BR level measurement after FFA initiation).

Results

Twenty‐two patients (median age 8.9 years, range 2.2–26.7) treated with BR were included. Median duration of BR–FFA combination therapy was 7 months (range 0–28). BR doses were reduced at least once in 11 patients (50%) as a precaution or because of increased serum levels. At T3, mean BR dose was significantly lower compared to T0 (1217 mg/day, SD = 699 vs. 1755 mg/day, SD = 752.2; p = 0.04), but BR levels showed no significant difference between T2 or T3 and baseline. In contrast, for patients with stable BR doses ( n = 14), mean BR level significantly increased from baseline (1376 mg/L, SD = 345.7) to T2 (1762 mg/L, SD = 553.3; p = 0.04). AEs were reported in 15 patients (68.2%) during the combination therapy, with the most common being somnolence (59.1%) and loss of appetite (22.7%). In 40.9% either FFA or BR were discontinued due to sedation. The responder rate for seizure reduction was 68.4% at 3 months and 76.9% at 6 months. Significance BR levels increased significantly after FFA initiation when BR doses were not reduced, contributing to adverse events—primarily somnolence—and resulting in the discontinuation of BR or FFA in some patients. Close monitoring of BR levels is crucial to minimize the risk of adverse events. Plain language summary This study investigated the combination of fenfluramine (FFA) and potassium BR in treating Dravet syndrome. It was found that it is effective in reducing seizures, but BR levels often went up after starting FFA, which caused side effects like drowsiness in many patients. In some cases, these side effects were serious enough that physicians had to stop either BR or FFA. The study highlights the need for careful monitoring of BR levels when using this combination to avoid potential side effects by reducing the BR dose early if needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsies, MyoclonicBromidesPotassium CompoundsFenfluramineAnticonvulsantsHumansFemaleMaleChildRetrospective StudiesChild, PreschoolAdolescentAdultYoung AdultDrug Therapy, CombinationTreatment Outcome

Stichwörter der Autor:innen

Dravet syndromedrug–drug interactionepilepsyfenfluraminepotassium bromideseizures

Substanzen

Bromidespotassium bromidePotassium CompoundsFenfluramineAnticonvulsants

Autor:innen und Institutionen

  • Clinic for Neuropediatrics and Neurorehabilitation, Epilepsy Center for Children and Adolescents, Schön Klinik Vogtareuth, Vogtareuth, Germany.
  • Congenital Heart Disease and Pediatric Cardiology, German Heart Centre Munich, TUM Universitätsklinikum, Munich, Germany.
  • Department of Pediatrics, Institute of Rehabilitation, Institute of Rehabilitation, Transition and Palliation of Neurologically Ill Children, Paracelsus Medical University Salzburg, Salzburg, Austria.
  • Department of Neurology, Goethe-University Frankfurt Epilepsy Center Frankfurt Rhine-Main, Frankfurt am Main, Germany.
  • Department of Pediatric Epileptology, Goethe-University Frankfur, Frankfurt am Main, Germany.
  • Epilepsy Center Kleinwachau, Radeberg, Germany.

ORCID-Profile: Adam Strzelczyk, Susanne Schubert-Bast, Tilmann Polster, Regina Trollmann, Kerstin A Klotz

Förderung

  • LOEWE - Personalized Translational Epilepsy Research, Goethe University Frankfurt
  • Faculty of Medicine, University of Freiburg
  • Medizinische Fakultät der Albert-Ludwigs-Universität Freiburg

Zitieren

APA

Pringsheim, M., Kluger, G., Strzelczyk, A., Schubert-Bast, S., Mayer, T., Glauche, B., Muhle, H., Alber, M., Spors, H., Polster, T., Trollmann, R., Kurlemann, G., Berndt, M., & Klotz, K. A. (2025). Efficacy and tolerability of fenfluramine with concomitant potassium bromide in patients with Dravet syndrome. Epilepsia Open. https://doi.org/10.1002/epi4.70079

Vancouver

Pringsheim M, Kluger G, Strzelczyk A, Schubert-Bast S, Mayer T, Glauche B, et al. Efficacy and tolerability of fenfluramine with concomitant potassium bromide in patients with Dravet syndrome. Epilepsia Open. 2025. doi:10.1002/epi4.70079

BibTeX
@article{Pringsheim2025,
  author = {Pringsheim, Milka and Kluger, Gerhard and Strzelczyk, Adam and Schubert-Bast, Susanne and Mayer, Thomas and Glauche, Benjamin and Muhle, Hiltrud and Alber, Michael and Spors, Hartwig and Polster, Tilmann and Trollmann, Regina and Kurlemann, Gerhard and Berndt, Markus and Klotz, Kerstin A},
  title = {Efficacy and tolerability of fenfluramine with concomitant potassium bromide in patients with Dravet syndrome},
  journal = {Epilepsia Open},
  year = {2025},
  doi = {10.1002/epi4.70079}
}
Kostenlos starten →